Analysis of clinical trials on therapies for prostate cancer in mainland China and globally from 2010 to 2020

K Chen, K Jiang, L Tang, X Chen, J Hu, F Sun - Frontiers in Oncology, 2021 - frontiersin.org
The overall aging of the world population has contributed to the continuous upward trend in
the incidence of prostate cancer (PC). Trials on PC therapy have been extensively …

Recent advances in the molecular targeted drugs for prostate cancer

P Gao, T Li, K Zhang, G Luo - International Urology and Nephrology, 2023 - Springer
Abstract Context Prostate cancer (PCa) is the second largest male tumor in the world and
one of the most common malignant tumors in the urinary system. In recent years, the …

Efficacy and safety of therapies for advanced prostate cancer in Asia: Evidence from a systematic literature review

M Saad, R Umbas, E Chiong… - … Advances in Medical …, 2022 - journals.sagepub.com
Objectives: Several therapies are available for the treatment of advanced/metastatic prostate
cancer (PC). However, the systematic assessment of evidence pertaining to the use of these …

Prostate cancer treatment–China's perspective

J Liu, L Dong, Y Zhu, B Dong, J Sha, HH Zhu, J Pan… - Cancer letters, 2022 - Elsevier
Prostate cancer (PCa) incidence and mortality have rapidly increased in China. Notably,
unique epidemiological characteristics of PCa are found in the Chinese PCa population …

[HTML][HTML] Prostate cancer clinical trials in low-and middle-income countries

SA Halaseh, A Al-Karadsheh, D Mukherji… - …, 2023 - ncbi.nlm.nih.gov
Background Prostate cancer is the second most common form of cancer and a leading
cause of cancer-related death in men. In an era of evidence-based medicine, clinical trials …

Prostate cancer and prostatic diseases best of Asia, 2019: challenges and opportunities

Y Zhu, SJ Freedland, D Ye - Prostate Cancer and Prostatic Diseases, 2020 - nature.com
The incidence of prostate cancer (PCa) varies widely among different ethnicities, while 73.7
per 100,000 in North America and 13.9 per 100,000 in East Asia [1]. Although the incidence …

[HTML][HTML] Comments on National guidelines for diagnosis and treatment of prostate cancer 2022 in China (English version)

Y Yang - Chinese Journal of Cancer Research, 2022 - ncbi.nlm.nih.gov
National guidelines for diagnosis and treatment of prostate cancer 2022 in China (English
version)(1) was organized by the National Health Commission of the People's Republic of …

United in Fight against prostate cancer registry (UFO): first results from a large, multi-center, prospective, longitudinal cohort study in Asia

H Uemura, D Ye, R Kanesvaran, H Zeng… - Annals of …, 2018 - annalsofoncology.org
Background: The way in which prostate cancer (PC) is diagnosed and treated is fragmented
across some Asian countries. We have established a PC registry (UFO) with the aim of …

[HTML][HTML] Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings

UM Vogl, TM Beer, ID Davis, ND Shore… - European Journal of …, 2022 - Elsevier
Background Innovations in treatments, imaging and molecular characterisation have
improved outcomes for people with advanced prostate cancer; however, many aspects of …

Treatment pathways of Japanese prostate cancer patients-a retrospective transition analysis with administrative data

S Cheung, Y Hamuro, J Mahlich, M Nakayama… - PLoS …, 2018 - journals.plos.org
Background Limited availability of real-world data that describe treatment patterns of
Japanese prostate cancer (PCA) patients. Methods A biweekly transition analysis of PCA …